Natural selection on the influenza virus genome

Molecular Biology and Evolution

Volumn 23, Issue 10, 2006, Pages 1902-1911

  Suzuki, Yoshiyuki ^a  

^a NATIONAL INSTITUTE OF GENETICS   (Japan)

Author keywords

Drug; Genome; Influenza virus; Negative selection; Positive selection; Vaccine

Indexed keywords

AMINO ACID; EPITOPE; HLA ANTIGEN; NUCLEOTIDE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; B LYMPHOCYTE; INFLUENZA; INFLUENZA VIRUS A; MOLECULAR EVOLUTION; NATURAL SELECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; T LYMPHOCYTE; VIROGENESIS; VIRUS GENOME;

ANTIGENS, VIRAL; B-LYMPHOCYTES; DNA, VIRAL; DRUG RESISTANCE, VIRAL; EPITOPES; EVOLUTION, MOLECULAR; GENOME, VIRAL; HUMANS; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; MUTATION; SELECTION (GENETICS); T-LYMPHOCYTES; VIRAL PROTEINS;

INFLUENZA A VIRUS; ORTHOMYXOVIRIDAE;

EID: 33748789595     PISSN: 07374038     EISSN: 15371719     Source Type: Journal    
DOI: 10.1093/molbev/msl050     Document Type: Article

References (81)

1. Adler S, Frank R, Lanzavecchia A, Weiss S. 1994. T cell epitope analysis with peptides simultaneously synthesized on cellulose membranes: fine mapping of two DQ dependent epitopes. FEBS Lett 352:167-70.
2. Air GM, Els MC, Brown LE, Laver WG, Webster RG. 1985. Location of antigenic sites on the three-dimensional structure of the influenza N2 virus neuraminidase. Virology 145:237-48.
3. Andersen MH, Sondergaard I, Zeuthen J, Elliott T, Haurum JS. 1999. An assay for peptide binding to HLA-Cw*0102. Tissue Antigens 54:185-90.
4. Berkhoff EGM, de Wit E, Geelhoed-Mieras MM, Boon ACM, Symons J, Fouchier RAM, Osterhaus ADME, Rimmelzwaan GF. 2005. Functional constraints of influenza A virus epitopes limit escape from cytotoxic T lymphocytes. J Virol 79: 11239-46.
5. Berlin S, Smith NGC. 2005. Testing for adaptive evolution of the female reproductive protein ZPC in mammals, birds and fishes reveals problems with the M7-M8 likelihood ratio test. BMC Evol Biol 5:65.
6. Boon ACM, de Mutsert G, Graus YMF, Fouchier RAM, Sintnicolaas K, Osterhaus ADME, Rimmelzwaan GF. 2002. Sequence variation in a newly identified HLA-B35-restricted epitope in the influenza A virus nucleoprotein associated with escape from cytotoxic T lymphocytes. J Virol 76:2567-72.
7. Bush RM, Bender CA, Subbarao K, Cox NJ, Fitch WM. 1999. Predicting the evolution of human influenza A. Science 286:1921-5.
8. Bush RM, Fitch WM, Bender CA, Cox NJ. 1999. Positive selection on the H3 hemagglutinin gene of human influenza virus A. Mol Biol Evol 16:1457-65.
9. Bush RM, Smith CB, Cox NJ, Fitch WM. 2000. Effects of passage history and sampling bias on phylogenetic reconstruction of human influenza A evolution. Proc Natl Acad Sci USA 97:6974-80.
10. Campitelli L, Ciccozzi M, Salemi M, Taglia F, Boros S, Donatelli I, Rezza G. 2006. H5N1 influenza virus evolution: a comparison of different epidemics in birds and humans (1997-2004). J Gen Virol 87:955-60.
11. Carmichael P, Copier J, So A, Lechler R. 1997. Allele-specific variation in the degeneracy of major histocompatibility complex (MHC) restriction. Hum Immunol 54:21-9.
12. Chen W, Calvo PA, Malide D, et al. (13 co-authors). 2001. A novel influenza A virus mitochondrial protein that induces cell death. Nat Med 7:1306-12.
13. Cox RJ, Brokstad KA, Ogra P. 2004. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol 59:1-15.
14. Crowe SR, Miller SC, Woodland DL. 2006. Identification of protective and non-protective T cell epitopes in influenza. Vaccine 24:452-6.
15. DiBrino M, Parker KC, Margulies DH, Shiloach J, Turner RV, Biddison WE, Coligan JE. 1994. The HLA-B14 peptide binding site can accommodate peptides with different combinations of anchor residues. J Biol Chem 269:32426-34.
16. DiBrino M, Parker KC, Margulies DH, Shiloach J, Turner RV, Biddison WE, Coligan JE. 1995. Identification of the peptide binding motif for HLA-B44, one of the most common HLA-B alleles in the Caucasian population. Biochemistry 34:10130-8.
17. DiBrino M, Tsuchida T, Turner RV, Parker KC, Coligan JE, Biddison WE. 1993. HLA-A1 and HLA-A3 T cell epitopes derived from influenza virus proteins predicted from peptide binding motifs. J Immunol 151:5930-5.
18. Dong T, Boyd D, Rosenberg W, Alp N, Takiguchi M, McMichael A, Rowland-Jones S. 1996. An HLA-B35-restricted epitope modified at an anchor residue results in an antagonist peptide. Eur J Immunol 26:335-9.
19. Ferguson NM, Galvani AP, Bush RM. 2003. Ecological and immunological determinants of influenza evolution. Nature 422:428-33.
20. Fitch WM. 1971. Toward defining the course of evolution: minimum change for a specific tree topology. Syst Zool 20:406-16.
21. Forsberg R, Christiansen FB. 2003. A codon-based model of host-specific selection in parasites, with an application to the influenza A virus. Mol Biol Evol 20:1252-9.
22. Ghedin E, Sengamalay NA, Shumway M, et al. (19 co-authors). 2005. Large-scale sequencing of human influenza reveals the dynamic nature of viral genome evolution. Nature 437:1162-6.
23. Gianfrani C, Oseroff C, Sidney J, Chesnut RW, Sette A. 2000. Human memory CTL response specific for influenza A virus is broad and multispecific. Hum Immunol 61:438-52.
24. Gog JR, Rimmelzwaan GF, Osterhaus AD, Grenfell BT. 2003. Population dynamics of rapid fixation in cytotoxic T lymphocyte escape mutants of influenza A. Proc Natl Acad Sci USA 100:11143-7.
25. Gotch F, McMichael A, Rothbard J. 1988. Recognition of influenza A matrix protein by HLA-A2-restricted cytotoxic T lymphocytes. J Exp Med 168:2045-57.
26. Gubareva LV, Kaiser L, Hayden FG. 2000. Influenza virus neuraminidase inhibitors. Lancet 355:827-35.
27. Guo HC, Jardetzky TS, Garrett TP, Lane WS, Strominger JL, Wiley DC. 1992. Different length peptides bind to HLA-Aw68 similarly at their ends but bulge out in the middle. Nature 360:364-6.
28. Hardy CT, Young SA, Webster RG, Naeve CW, Owens RJ. 1995. Egg fluids and cells of the chorioallantoic membrane of embryonated chicken eggs can select different variants of influenza A (H3N2) viruses. Virology 211:302-6.
29. Hay AJ, Wolstenholme AJ, Skehel JJ, Smith MH. 1985. The molecular basis of the specific anti-influenza action of amantadine. EMBO J 4:3021-4.
30. Hoffmann E, Neumann G, Kawaoka Y, Hobom G, Webster RG. 2000. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci USA 97:6108-13.
31. Holmes EC, Ghedin E, Miller N, et al. (11 co-authors). 2005. Whole-genome analysis of human influenza A virus reveals multiple persistent lineages and reassortment among recent H3N2 viruses. PLoS Biol 3:e300.
32. Huet S, Nixon DF, Rothbard JB, Townsend A, Ellis SA, McMichael AJ. 1990. Structural homologies between two HLA B27-restricted peptides suggest residues important for interaction with HLA B27. Int Immunol 2:311-6.
33. Hughes AL, Nei M. 1988. Pattern of nucleotide substitution at major histocompatibility complex class I loci reveals over-dominant selection. Nature 335:167-70.
34. Jameson J, Cruz J, Terajima M, Ennis FA. 1999. Human CD8+ and CD4+ T lymphocyte memory to influenza A viruses of swine and avian species. J Immunol 162:7578-83.
35. Jin H, Zhou H, Liu H, Chan W, Adhikary L, Mahmood K, Lee MS, Kemble G. 2005. Two residues in the hemagglutinin of A/Fujian/411/02-like influenza viruses are responsible for antigenic drift from A/Panama/2007/99. Virology 336:113-9.
36. Jones CM, Lake RA, Lamb JR, Faith A. 1994. Degeneracy of T cell receptor recognition of an influenza virus hemagglutinin epitope restricted by HLA-DQ and -DR class II molecules. Eur J Immunol 24:1137-42.
37. Kilbourne ED, Smith C, Brett I, Pokorny BA, Johansson B, Cox N. 2002. The total influenza vaccine failure of 1947 revisited: major intrasubtypic antigenic change can explain failure of vaccine in a post-World War II epidemic. Proc Natl Acad Sci USA 99:10748-52.
38. Kimura M. 1980. A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences. J Mol Evol 16:111-20.
39. Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, Kimura K, Hayden FG, Sugaya N, Kawaoka Y. 2004. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364:759-65.
40. Klein J, Horejsi V. 1997. Immunology. 2nd ed. Oxford: Blackwell Science Ltd.
41. Macken C, Lu H, Goodman J, Boykin L. 2001. The value of a database in surveillance and vaccine selection. In: Osterhaus ADME, Cox N, Hampson AW, editors. Options for the control of influenza IV. Amsterdam: Elsevier Science. p 103-6.
42. Man S, Newberg MH, Crotzer VL, Luckey CJ, Williams NS, Chen Y, Huczko EL, Ridge JP, Engelhard VH. 1995. Definition of a human T cell epitope from influenza A non-structural protein 1 using HLA-A2.1 transgenic mice. Int Immunol 7:597-605.
43. + cytotoxic T cells to virus clearance or pathologic manifestations of influenza virus infection in a T cell receptor transgenic mouse model. J Exp Med 188:223-32.
44. Mostow SR, Schoenbaum SC, Dowdle WR, Coleman MT, Kaye HS, Hierholzer JC. 1970. Studies on inactivated influenza vaccines. II. Effect of increasing dosage on antibody response and adverse reactions in man. Am J Epidemiol 92:248-56.
45. Nei M. 1983. Genetic polymorphism and the role of mutation in evolution. In: Nei M, Koehn RK, editors. Evolution of genes and proteins. Sunderland, MA: Sinauer. p 165-90.
46. Nei M, Kumar S. 2000. Molecular evolution and phylogenetics. Oxford: Oxford University Press.
47. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W. 1999. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 5:1157-63.
48. Noda T, Sagara H, Yen A, Takada A, Kida H, Cheng RH, Kawaoka Y. 2006. Architecture of ribonucleoprotein complexes in influenza A virus particles. Nature 439:490-2.
49. Obenauer JC, Denson J, Mehta PK, et al. (17 co-authors). 2006. Large-scale sequence analysis of avian influenza isolates. Science 311:1576-80.
50. O'Sullivan D, Sidney J, del Guercio MF, Colon SM, Sette A. 1991. Truncation analysis of several DR binding epitopes. J Immunol 146:1240-6.
51. Plotkin JB, Dushoff J, Levin SA. 2002. Hemagglutinin sequence clusters and the antigenic evolution of influenza A virus. Proc Natl Acad Sci USA 99:6263-8.
52. Powers DC, Belshe RB. 1993. Effect of age on cytotoxic T lymphocyte memory as well as serum and local antibody responses elicited by inactivated influenza virus vaccine. J Infect Dis 167:584-92.
53. Rohrlich PS, Cardinaud S, Firat H, Lamari M, Briand P, Escrious N, Lemonier FA. 2002. HLA-B*0702 transgenic, H-2KbDb double-knockout mice: phenotypical and functional characterization in the response to influenza. Int Immunol 15: 765-72.
54. Rothbard JB, Lechler RI, Howland K, Bal V, Eckels DD, Sekaly R, Long EO, Taylow WR, Lamb JR. 1988. Structural model of HLA-DR1 restricted T cell antigen recognition. Cell 52:515-23.
55. Saitou N. 1989. A theoretical study of the underestimation of branch lengths by the maximum parsimony principle. Syst Zool 38:1-6.
56. Saitou N, Nei M. 1987. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol 4:406-25.
57. Smith DJ, Lapedes AS, de Jong JC, Bestebroer TM, Rimmelzwaan GF, Osterhaus ADME, Fouchier RAM. 2004. Mapping the antigenic and genetic evolution of influenza virus. Science 305:371-6.
58. Smith W, Andrewes CH, Laidlaw PP. 1933. A virus obtained from influenza patients. Lancet 225:66-8.
59. Stern LJ, Brown JH, Jardetzky TS, Gorga JC, Urban RG, Strominger JL, Wiley DC. 1994. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 368:215-21.
60. Sutton J, Rowland-Jones S, Rosenberg W, et al. (12 co-authors). 1993. A sequence pattern for peptides presented to cytotoxic T lymphocytes by HLA B8 revealed by analysis of epitopes and eluted peptides. Eur J Immunol 23:447-53.
61. Suzuki Y. 2004a. Negative selection on neutralization epitopes of poliovirus surface proteins: implications for prediction of candidate epitopes for immunization. Gene 328:127-33.
62. Suzuki Y. 2004b. New methods for detecting positive selection at single amino acid sites. J Mol Evol 59:11-9.
63. Suzuki Y. 2004c. Three-dimensional window analysis for detecting positive selection at structural regions of proteins. Mol Biol Evol 21:2352-9.
64. Suzuki Y, Gojobori T. 1999. A method for detecting positive selection at single amino acid sites. Mol Biol Evol 16:1315-28.
65. Suzuki Y, Gojobori T. 2001. Positively selected amino acid sites in the entire coding region of hepatitis C virus subtype 1b. Gene 276:83-7.
66. Suzuki Y, Gojobori T, Nei M. 2001. ADAPTSITE: detecting natural selection at single amino acid sites. Bioinformatics 17:660-1.
67. Suzuki Y, Nei M. 2002. Origin and evolution of influenza virus hemagglutinin genes. Mol Biol Evol 19:501-9.
68. Suzuki Y, Nei M. 2004. False-positive selection identified by ML-based methods: examples from the Sig1 gene of the diatom Thalassiosira weissflogii and the tax gene of a human T-cell lymphotropic virus. Mol Biol Evol 21:914-21.
69. Thomas PG, Keating R, Hulse-Post DJ, Doherty PC. 2006. Cell-mediated protection in influenza infection. Emerg Infect Dis 12:48-54.
70. Thompson JD, Higgins DG, Gibson TJ. 1994. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 22:4673-80.
71. Townsend AR, Rothbard J, Gotch FM, Bahadur G, Wraith D, McMichael AJ. 1986. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 44:959-68.
72. Tussey LG, Rowland-Jones S, Zheng TS, Androlewicz MJ, Cresswell P, Frelinger JA, McMichael AJ. 1995. Different MHC class I alleles compete for presentation of overlapping viral epitopes. Immunity 3:65-77.
73. Vartdal F, Johansen BH, Friede T, Thorpe CJ, Stevanovic S, Eriksen JE, Sletten K, Thorsby E, Rammensee HG, Sollid LM. 1996. The peptide binding motif of the disease associated HLA-DQ (alpha 1* 0501, beta 1* 0201) molecule. Eur J Immunol 26:2764-72.
74. Venkatramani L, Bochkareva E, Lee JT, Gulati U, Laver WG, Bochkarev A, Air GM. 2006. An epidemiologically significant epitope of a 1998 human influenza virus neuraminidase forms a highly hydrated interface in the NA-antibody complex. J Mol Biol 356:651-63.
75. Webster RG, Kawaoka Y, Bean WJ. 1986. Vaccination as a strategy to reduce the emergence of amantadine- and rimantadine-resistant strains of A/Chick/Pennsylvania/83 (H5N2) influenza virus. J Antimicrob Chemother 18:157-64.
76. Wedermeyer H, Mizukoshi E, Davis AR, Bennink JR, Rehermann B. 2001. Cross-reactivity between hepatitis C virus and influenza A virus determinant specific cytotoxic T cells. J Virol 75:11392-400.
77. Wiley DC, Wilson IA, Skehel JJ. 1981. Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature 289:373-8.
78. World Health Organization. 1980. A revision of the system of nomenclature for influenza viruses: a WHO memorandum. Bull WHO 58:585-91.
79. Yen HL, Herlocher LM, Hoffmann E, Matrosovich MN, Monto AS, Webster RG, Govorkova EA. 2005. Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob Agents Chemother 49:4075-84.
80. Zebedee SL, Lamb RA. 1988. Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. J Virol 62:2762-72.
81. Zharikova D, Mozdzanowska K, Feng J, Zhang M, Gerhard W. 2005. Influenza type A virus escape mutants emerge in vivo in the presence of antibodies to the ectodomain of matrix protein 2. J Virol 79:6644-54.